107 related articles for article (PubMed ID: 10408763)
1. Effect of calcitriol and pamidronate in multiple myeloma.
Imseis RE; Palmieri GM; Holbert JM; Leventhal MR; Sebes JI
Am J Med Sci; 1999 Jul; 318(1):61-6. PubMed ID: 10408763
[TBL] [Abstract][Full Text] [Related]
2. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate.
Bianda T; Linka A; Junga G; Brunner H; Steinert H; Kiowski W; Schmid C
Calcif Tissue Int; 2000 Aug; 67(2):116-21. PubMed ID: 10920215
[TBL] [Abstract][Full Text] [Related]
3. Biochemical response to treatment of bone hyperresorption in chronically critically ill patients.
Nierman DM; Mechanick JI
Chest; 2000 Sep; 118(3):761-6. PubMed ID: 10988200
[TBL] [Abstract][Full Text] [Related]
4. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.
Chapurlat RD; Hugueny P; Delmas PD; Meunier PJ
Bone; 2004 Jul; 35(1):235-42. PubMed ID: 15207763
[TBL] [Abstract][Full Text] [Related]
5. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
7. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma.
Terpos E; Palermos J; Tsionos K; Anargyrou K; Viniou N; Papassavas P; Meletis J; Yataganas X
Eur J Haematol; 2000 Nov; 65(5):331-6. PubMed ID: 11092464
[TBL] [Abstract][Full Text] [Related]
8. Combined calcitriol-pamidronate therapy for bone hyperresorption in spinal cord injury.
Chen B; Mechanick JI; Nierman DM; Stein A
J Spinal Cord Med; 2001; 24(4):235-40. PubMed ID: 11944781
[TBL] [Abstract][Full Text] [Related]
9. Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect.
Martín A; García-Sanz R; Hernández J; Bladé J; Suquía B; Fernández-Calvo J; González M; Mateo G; Orfao A; San Miguel JF
Br J Haematol; 2002 Jul; 118(1):239-42. PubMed ID: 12100153
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of low doses of pamidronate in osteopenic patients administered in the early post-renal transplant.
Torregrosa JV; Fuster D; Monegal A; Gentil MA; Bravo J; Guirado L; Muxí A; Cubero J
Osteoporos Int; 2011 Jan; 22(1):281-7. PubMed ID: 20229199
[TBL] [Abstract][Full Text] [Related]
11. Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma.
Abildgaard N; Rungby J; Glerup H; Brixen K; Kassem M; Brincker H; Heickendorff L; Eriksen EF; Nielsen JL
Eur J Haematol; 1998 Aug; 61(2):128-34. PubMed ID: 9714526
[TBL] [Abstract][Full Text] [Related]
12. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Berenson JR; Lichtenstein A; Porter L; Dimopoulos MA; Bordoni R; George S; Lipton A; Keller A; Ballester O; Kovacs MJ; Blacklock HA; Bell R; Simeone J; Reitsma DJ; Heffernan M; Seaman J; Knight RD
N Engl J Med; 1996 Feb; 334(8):488-93. PubMed ID: 8559201
[TBL] [Abstract][Full Text] [Related]
14. Pamidronate and calcitriol trial for the prevention of early bone loss after renal transplantation.
Nam JH; Moon JI; Chung SS; Kim SI; Park KI; Song YD; Kim KR; Lee HC; Huh K; Lim SK
Transplant Proc; 2000 Nov; 32(7):1876. PubMed ID: 11119979
[No Abstract] [Full Text] [Related]
15. Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
Huang CY; Zheng CM; Wu CC; Lo L; Lu KC; Chu P
Nephron Clin Pract; 2012; 122(3-4):93-101. PubMed ID: 23635416
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium.
Winer KK; Ko CW; Reynolds JC; Dowdy K; Keil M; Peterson D; Gerber LH; McGarvey C; Cutler GB
J Clin Endocrinol Metab; 2003 Sep; 88(9):4214-20. PubMed ID: 12970289
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor activity of pamidronate in human multiple myeloma.
Kondo H; Mori A
Leuk Lymphoma; 2002 Apr; 43(4):919-21. PubMed ID: 12153188
[TBL] [Abstract][Full Text] [Related]
18. Anti-myeloma activity of pamidronate in vivo.
Dhodapkar MV; Singh J; Mehta J; Fassas A; Desikan KR; Perlman M; Munshi NC; Barlogie B
Br J Haematol; 1998 Nov; 103(2):530-2. PubMed ID: 9827929
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
Chapurlat RD; Delmas PD; Liens D; Meunier PJ
J Bone Miner Res; 1997 Oct; 12(10):1746-52. PubMed ID: 9333137
[TBL] [Abstract][Full Text] [Related]
20. Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: the effect on serum IL-1 and IL-6 levels and bone mineral density.
Türk S; Akbulut M; Yildiz A; Gürbilek M; Gönen S; Tombul Z; Yeksan M
Nephron; 2002 Feb; 90(2):188-94. PubMed ID: 11818704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
